|
 Molgramostim
(rHuGM-CSF,TOPLEUCON)
Recombinant Human Granulocyte Macrophage
Colony Stimulating Factor
Indication:
- Prevention and treatment of leucopenia caused by chemotherapy
or radiotherapy of tumour
- Treatment of bone marrow hematopoietic malflaction and myelodysplastic
syndrome
- Prevention of potential infection complication induced by leucopenia
- Acceleration of recovery of neutropenia induced by infections
Feature:
- Te'erli™ (molgramostim, rHuGM-CSF) is a recombinant protein,
and displays a broader range of haematopoietic activities.
- Te'erli™ interacts with early, multipotent progenitor cells,
promoting the proliferation and differentiation of burst and colony-forming
units.
- It not only reverses the neutropenia of myelodysplastic syndrome
and aplastic anemia, but also enhances recovery from bone marrow
transplantation and thus reduce the attendant morbidity of this
procedure.
- Te'erli™ rapidly recovers neutropenia during anti-cancer
chemotherapy and shortens the period during which patients are
supposed to the risk of infection and thereby enables us to complete
planned anti-cancer chemotherapies.
Te'erli™ finished its clinical trial in March 1997. The results
show that Te'erli™ is a cytokine with therapeutic effect and
safety. It can shorten markedly the duration of leucopenia and neutropenia.
- P.R.C. Government License No. (98) XIATEBAO S-01; S-02; S-03
- China Certification of GMP for Human Drugs (No. B0272)
- The first domestic marketing Molgramostim in China
Related link: www.amoytop.com
|